The opportunity
Demand for genomic benefits is growing. Value should too.
Genomic health benefits are quickly becoming a fixture in competitive benefits packages. But most tests being offered — including those deployed at Fortune 500 companies — sequence less than 2% of the genome, cover only one disease area, or come without clinical support1–3. MyOme sequences the whole genome, surfaces risk across diseases and medication response, and includes board-certified genetic counseling with every result.
1. Cohn B, et al. Molecular Genetics & Genomic Medicine (2023). 2. Society for Human Resource Management, 2018 Employee Benefits. 3. McDonald WS, et al. Molecular Genetics & Genomic Medicine (2020).
MyOme benefits package
Whole-genome coverage, not a 2% panel
Medication response
70+ medicationsComplex disease risk
Genetic counseling
Board-certified consultations included with every result.
Learn moreReduce healthcare spend
How genomic risk insights shape care
Many of the most expensive healthcare claims stem from conditions that can be identified and addressed earlier. MyOme Atlas tests uncover disease risk and medication response insights before conditions progress or medication-related events occur, enabling more proactive care, lower-cost interventions, and more effective prescribing.
Savings in treatment costs
Curated Screen insights for cancers, including breast cancer, can stimulate early screening, detection, and treatment. Treating breast cancer early can reduce treatment costs by >$500K.1
Savings in post-event care
Polygenic risk scores for coronary artery disease can lead to early interventions — like statin therapy — that reduce heart event risk and avoid $40K in annual treatment costs.2
Reduction in hospitalizations
Medication Response insights enable safe prescribing from the start. This type of screening is proven to reduce medication-related ER visits and inpatient stays by ~40%.3
- Reddy SR, Chung KC, Kansal AR, et al. Current Medical Research and Opinion. 2022; 38(5):791-800. doi: 10.1080/03007995.2022.2047536.
- Kazi DS, Elkind MSV, Deutsch A, et al. Circulation. 23 Jul 2024; 150(4):e89-e101. doi: 10.1161/CIR.0000000000001258.
- Fragala MS, Keogh M, Goldberg SE, Lorenz RA, and Shaman JA. The Pharmacogenomics Journal. 2 Oct 2024; 24(5):30. doi: 10.1038/s41397-024-00350-1.
Continuous value
A single genomic test delivers lifelong value
By transforming whole-genome data into a continuously updated resource, MyOme helps uncover new health insights that continue to drive better care and healthcare savings year after year.
Positive net savings in first year
Significant net savings start in second year
Net savings continue to compound
*Modeled data for an active employer program.
Proven uptake and impact
A benefit employees actually use
Employee participation
44%of employees engaged in the program within 90 days of access to MyOme testing
Disease risk detection
~14%of employees tested carried at least one clinically significant, high-impact risk variant linked to a health condition
High-risk classification
~20%of employees were identified as high-risk for cardiometabolic disease or cancer
Results averaged across active employer programs.
What our partners say
More than 50% of cancers and up to 80% of cardiac diseases are preventable. By integrating genomics into employer health programs, we provide participants with knowledge that can save lives and significantly improve outcomes.
Employee support and privacy
Results are the employee's — always
Every employee receives their results privately, with access to a certified genetic counselor to help them understand findings and plan next steps. Your organization sees only aggregate, de-identified program data — never individual results. All genomic data is encrypted, HIPAA-compliant, and never shared without the employee's explicit consent.
Privacy and security
Ready to bring genomic benefits to your clients?
Whether you're evaluating options for a specific employer or building genomics into your standard benefits toolkit, our team can walk you through program structure, pricing, and what implementation looks like in practice.